What are the key advantages of DNA/RNA vaccines?

DNA/RNA vaccines offer rapid development, strong cellular immunity, and flexibility against emerging pathogens.

How do DNA and RNA vaccines differ?

DNA vaccines require nuclear entry for expression, while RNA vaccines work directly in the cytoplasm.

What delivery methods are used for DNA/RNA vaccines?

Electroporation (DNA) and lipid nanoparticles (LNP, RNA) enhance cellular uptake and immunogenicity.

How is immunogenicity optimized in nucleic acid vaccines?

Codon optimization, UTR modifications, and adjuvant co-delivery improve antigen expression and immune responses.

Can DNA/RNA vaccines target multiple pathogens?

Yes, multi-epitope or multiplex designs enable broad protection against variants or co-infections.

What are the challenges in DNA/RNA vaccine stability?

RNA degradation and plasmid DNA shelf-life require optimized formulations (e.g., LNPs, lyophilization).

DNA and RNA Vaccine Solution

Creative Biolabs offers comprehensive preclinical services for nucleic acid vaccine development, including DNA and RNA vaccine design, optimization, and validation. Our expertise covers antigen selection, vector construction, and immunogenicity evaluation in animal models. We utilize advanced platforms for mRNA synthesis, lipid nanoparticle (LNP) encapsulation, and quality control to ensure high-purity, stable vaccine candidates. Additionally, we provide in vitro and in vivo efficacy testing and toxicity assessments to accelerate IND-enabling studies. With a proven track record in vaccine development, we deliver tailored solutions to meet diverse research and clinical needs.

Talk To Our Vaccine Experts View Services Available products

End-to-end DNA and RNA vaccine solutions

What is a DNA and RNA vaccine?

A DNA or RNA vaccine is a type of nucleic acid vaccine that delivers genetic material encoding an antigen into the body. Once inside cells, this genetic material uses the host’s own machinery to produce the antigenic protein, triggering an immune response. Unlike traditional vaccines, which use weakened or inactivated pathogens, nucleic acid vaccines contain only DNA or RNA, making them easier and faster to produce. DNA vaccines typically use plasmids, while RNA vaccines use messenger RNA (mRNA). These vaccines have shown promise in infectious disease and cancer immunotherapy due to their safety, scalability, and ability to induce both humoral and cellular immunity.

Comprehensive DNA and RNA Vaccine Preclinical Solution

Creative Biolabs provides comprehensive DNA and RNA vaccine design services, leveraging advanced molecular techniques to develop custom nucleic acid vaccines for infectious diseases and cancer. Our services include antigen design, plasmid or mRNA construction, optimization, and preclinical validation. With a focus on safety, efficacy, and rapid development, we support researchers in creating next-generation vaccines tailored to specific targets.

Comprehensive Service Portfolio

Vaccine Design Adjuvant selection Analysis & ValidationFormulation Development Preclinical Testing

Customized DNA and RNA Vaccine Design

Targeted Antigen Design: Precision engineering of DNA/RNA sequences for optimal expression of pathogen-specific antigens (e.g., viral spike proteins, bacterial toxins) with enhanced immunogenicity.
Multi-Epitope Constructs: Development of multi-antigen vaccines targeting 2-4 conserved epitopes to overcome pathogen variability and provide broad protection.
Advanced Vector Engineering: Optimized DNA plasmid backbones and RNA constructs with modified nucleosides for improved stability and translation efficiency.

Adjuvant Development & Optimization

Nucleic Acid-Specific Adjuvant Screening: Specialized evaluation of TLR agonists (e.g., TLR3/7/8/9 ligands) and STING activators optimized for DNA/RNA vaccine platforms.
Delivery-Enhanced Adjuvant Systems: Development of LNP-formulated adjuvants that co-deliver nucleic acid payloads and immunostimulants to the same cell populations.
Balanced Immunity Optimization: Precision tuning of adjuvant combinations to achieve optimal Th1/Th2 bias for specific disease targets (e.g., viral vs. cancer vaccines).

Analytical Development & Preclinical Validation

Comprehensive Molecular Characterization: Advanced analytical methods including ddPCR for plasmid copy number, RNA integrity analysis (RIN), and LNP characterization (DLS, HPLC).
Functional Immunogenicity Testing: Multiplexed evaluation of humoral (neutralizing antibodies) and cellular (ELISpot, ICS) responses in rodent/NHP models.
Safety Assessment: Thorough toxicity profiling including biodistribution studies and local/systemic reactogenicity evaluation.
Process-Related Impurity Control: Sensitive detection of residual DNA/RNA, host cell proteins, and process contaminants to GMP standards.

Formulation & Process Development

Advanced Delivery Formulations: Development of optimized LNP and polymeric nanoparticle systems for enhanced DNA/RNA stability and cellular uptake.
Process Scale-Up Solutions: GMP-compliant scale-up of nucleic acid production from mg to kg scale with stringent QC controls.
Lyophilization & Stability Testing: Specialized formulation development for thermostable vaccines including accelerated stability studies.

Preclinical Testing

In Vivo Efficacy Studies: We use diverse animal models like rodents and non-human primates. Conduct challenge studies to directly assess vaccine-induced protection. Analyze immune correlates to understand how the vaccine stimulates an effective immune response for better vaccine design.

Featured DNA and RNA Vaccine Design Services

Self-Amplifying mRNA Vaccine Platform

Enables sustained antigen expression with minimal doses;
Incorporates replicase sequences for enhanced immunogenicity;
Ideal for rapid response to emerging pathogens.

mRNA Vaccine Platform

Supports flexible sequence modification;
Rapid design-to-production turnaround;
Optimized for balanced potency and safety;
Suitable for diverse infectious disease targets.

Non-Replicating mRNA Vaccine Platform

Lower biosafety risk with controlled expression;
Stable in various formulations;
Compatible with multiple delivery systems for broad applicability.

mRNA Pharmacology Optimization Platform

Fine-tunes codon usage and 5'/3' UTRs;
Enhances stability and translation efficiency;
Reduces off-target effects through sequence engineering.

Custom GMP-grade mRNA Synthesis

Complies with strict quality standards;
Scalable production from mg to kg levels;
Customizable modifications (capping, polyadenylation) for research and preclinical needs.

How Dose DNA and RNA Vaccine Solution Work?

1. Antigen Design and Optimization

Pathogen genome analysis based on high-throughput sequencing platform
AI online platform predicts highly immunogenic epitopes
Optimizing and modifying candidate antigens to enhance their immunogenicity and stability.

2. Immunization Strategy Development

Outer Membrane Vesicle Platform induces antigen expression
Optimization of adjuvant compatibility (aluminum adjuvant, TLR agonist)
Delivery system customization (nanoparticles/liposomes)

3. Immunogenicity Assessment

Humoral immunity testing (IgG/IgA subtypes, neutralizing antibody titers)
Cellular immune assay (Th1/Th2/Th17 response profile)
ADCP/ADCD functional verification

4. Animal Model Verification

Customized challenge model (mouse/guinea pig/rabbit)
Protection effectiveness evaluation (LD50, bacterial load monitoring)
Safety assessment (local/systemic toxicity)

5. Report

Screening analysis reports
Test data reports
Project design document

Online Inquiry

Getting Started with Your Vaccine Project

Professional Vaccine Solution platform

Antigen Prediction System Platform

Our Antigen Prediction System Platform integrates advanced bioinformatics and computational biology tools to identify and prioritize immunogenic antigens. Leveraging cutting-edge algorithms, we analyze pathogen genomes or cancer markers to predict key epitopes that elicit robust immune responses. This platform enables the rational design of vaccines by pinpointing high-potency antigens, significantly accelerating the development process for bacterial, viral, fungal, parasitic, and cancer-targeted vaccines. By combining traditional immunology with state-of-the-art predictive modeling, we ensure optimal antigen selection for maximum immunogenicity and efficacy.

Protein Expression Platform

The Protein Expression Platform at Creative Biolabs offers versatile solutions for producing recombinant antigens using multiple expression systems. We specialize in optimizing bacterial (e.g., E. coli), yeast, insect, and mammalian cell systems to meet diverse production needs. Our expertise in genetic engineering allows us to tailor expression vectors, culture conditions, and purification protocols for high-yield, biologically active proteins. Whether for preclinical research or large-scale manufacturing, our platform ensures consistent production of immunogenic proteins, supporting the development of vaccines with enhanced stability and immunogenicity. We seamlessly integrate expression technologies with downstream analytical and formulation services to streamline the vaccine development pipeline.

Modular Delivery System Platform

Our Modular Delivery System Platform is designed to enhance vaccine potency and delivery efficiency through customizable, multi-component formulations. Focused on optimizing delivery mechanisms, we develop lipid-based nanoparticles, viral-like particles (VLPs), and other nano-carriers to protect antigens, improve cellular uptake, and modulate immune responses. The modular design allows for precise integration of adjuvants, targeting ligands, and protective matrices, enabling tailor-made systems for various vaccine types—from prophylactic to therapeutic.

Why Choose Our DNA and RNA Vaccine Services?

Comprehensive Nucleic Acid Vaccine Platform

Creative Biolabs provides end-to-end DNA and RNA vaccine solutions, utilizing cutting-edge technologies including mRNA-LNP formulations, DNA plasmids, and self-amplifying RNA platforms for diverse disease targets.

Broad-Spectrum Pathogen Coverage

Our services cover vaccines against viral pathogens (influenza, SARS-CoV-2), bacterial targets, and cancer neoantigens, addressing both preventive and therapeutic applications.

Advanced Formulation and Quality Assurance

We employ optimized LNP encapsulation, codon optimization, and stringent QC testing (HPLC, ddPCR) to ensure vaccine stability, potency, and batch-to-batch consistency.

Integrated Research-to-Clinical Pipeline

From bioinformatics design and preclinical testing to GMP manufacturing, we offer complete development solutions for accelerated IND approval.

Available Products

Antigen Products Antibody Products Adjuvant Products Delivery System related Products

Array Kits Cell Culture Medium Proudcts

FAQs

What are the key advantages of DNA/RNA vaccines?

DNA/RNA vaccines offer rapid development, strong cellular immunity, and flexibility against emerging pathogens.
How do DNA and RNA vaccines differ?

DNA vaccines require nuclear entry for expression, while RNA vaccines work directly in the cytoplasm.
What delivery methods are used for DNA/RNA vaccines?

Electroporation (DNA) and lipid nanoparticles (LNP, RNA) enhance cellular uptake and immunogenicity.
How is immunogenicity optimized in nucleic acid vaccines?

Codon optimization, UTR modifications, and adjuvant co-delivery improve antigen expression and immune responses.
Can DNA/RNA vaccines target multiple pathogens?

Yes, multi-epitope or multiplex designs enable broad protection against variants or co-infections.
What are the challenges in DNA/RNA vaccine stability?

RNA degradation and plasmid DNA shelf-life require optimized formulations (e.g., LNPs, lyophilization).

Related Resources

Download Resources

Literature Center

Podcast